RSV infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown.

Whether vaccination during pregnancy could reduce the burden of RSV associated lower respiratory tract illness in newborns and infants is uncertain.

Early-life severe RSV infection has been associated with the onset of childhood wheezing illnesses. However, the relationship between RSV infection during infancy and the development of childhood asthma is unclear.

SARS-CoV-2 infection may lead to acute and chronic sequelae. Emerging evidence suggests a higher risk of diabetes after infection, but population-based evidence is still sparse.

It’s estimated that half a million or more people around the world die of influenza each year. And many of these deaths could be prevented with a highly effective, widely used flu shot.

Ahead of European Immunisation Week (EIW), taking place from 23 to 29 April 2023, Isabel de la Mata -principal advisor for Health and Crisis Management at the European Commission- talks about the benefits of lifelong vaccination

This systematic review and meta-analysis aims to explore changes in sleep quality and sleep disturbances in the general population from before to during the COVID-19 lockdown.

With the World Immunization Week coming up, IFA has produced a study to deliver critical baseline data to help inform technical guidelines, as well as governmental and civil society dialogue and policy actions, to protect the health of LTC residents.

Accurate health-care burden data in healthy infants are necessary to determine RSV immunisation policy when RSV immunisation becomes available.

It provides an overview of the project results at the end of 2 years of collaborative work: the training tools and resources designed to support health professionals in their vaccine communication efforts and the advocacy campaigns.

The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in humans, but the emergence of highly infectious variants necessitated additional doses and the development of new variant-derived vaccines.

Main outcome of the ESWI summit “Pandemic Preparedness: Where Science and Policy Meet”, which took place in Brussels in June 2022, was recently published in the scientific journal One Health Outlook.